ABM-1310 is a novel small molecule BRAF inhibitor that has shown promising anti-cancer activity and a good safety profile across a variety of advanced BRAF V600-mutant solid tumors.
The FDA has granted an orphan drug designation (ODD) to ABM-1310 for the treatment of patients with glioblastoma (GBM) harboring a BRAF V600 mutation, according to ABM Therapeutics, Inc.1
ABM-1310 is a novel small molecule BRAF inhibitor that is orally administered. The product has high BRAF-mutation selectivity, high water solubility, and high blood-brain barrier permeability, and is currently being developed by ABM Therapeutics, Inc. Multiple phase 1 studies are ongoing, evaluating ABM-1310 across clinical sites in the United States and China in patients with BRAF V600-mutant advanced solid tumors.
Interim findings from a phase 1 study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 showed ABM-1310 to have promising anticancer activity and a good safety profile when used for the treatment of patients with advanced BRAF V600-mutant solid tumors. This included in patients with primary brain tumors, such as GBM and other gliomas.2
In the multicenter, open-label, dose-escalation trial, patients with BRAF V600-mutated solid tumors were enrolled and assessed to determine the primary end point of maximum tolerated dose and recommended phase 2 dose of ABM-1310 with or without cobimetinib (Cotellic), along with secondary end points of safety, tolerability, pharmacokinetics, and preliminary efficacy.
Findings revealed that as of November 28, 2022, 20 patients with a median age of 57.5 years were enrolled and treated with ABM-1310 monotherapy across 6 dose levels in part A of the study. Sixteen patients in part A were efficacy evaluable and among them, 2 had a partial response (PR) and 8 had stable disease (SD) as their best response.
Among patients, 100% experienced adverse events (AEs), with the most frequent being skin rash (40%) and QT prolongation (20%). Drug-related grade ≥3 AEs occurred in 3 patients and consisted of nausea/vomiting, QT prolongation and rash, and 2 patients had drug-related serious AEs, including nausea/vomiting and creatinine increase.
In part B of the study, ABM-1310 in combination with cobimetinib was assessed at 2 dose levels, 100 mg twice a day (n = 3) and 200 mg twice a day (n = 3). Four patients had AEs and drug-related AEs, including rash and QT prolongation, and no SAEs were reported. Of the 3 evaluable patients, 1 patient with melanoma had a PR and 1 had SD as their best response.
No DLTs were confirmed in either dose-escalation part of the trial and no patients discontinued treatment prematurely for any safety or tolerability reason. Additionally, no drug-related deaths were reported.
Overall, ABM-1310 at doses up to 200 mg twice a day, either alone with cobimetinib, was generally well tolerated, with no new safety signals. This trial is ongoing.
Additionally, a new phase 1 clinical trial taking place in China has been initiated, specifically evaluating ABM-1310 to target GBM.